利用树突状细胞开发肺癌癌症疫苗的进展（综述）

Lung cancer is a major global health concern in terms of both incidence and mortality. Despite substantial advancements in targeted therapy and immune checkpoint inhibitor treatments, their overall effectiveness is limited. Dendritic cells (DCs) are crucial in innate and acquired immune responses due to their effective presentation of antigens. DC-based cancer vaccines have been identified as promising strategies for personalized cancer immunotherapy.

The present review presents a thorough examination of the immunomodulation and associated mechanisms of DC vaccines in lung cancer, with a specific emphasis on the presentation of clinical trial data concerning the safety, feasibility and effectiveness of DC vaccines in the treatment of patients with lung cancer. The objective of this review is to highlight strategies and provide insights that may improve the development and clinical efficacy of DC vaccines for the treatment lung cancer.